Press release

Elucid Bioimaging Relocates Headquarters to Downtown Boston

0
Sponsored by Businesswire

Elucid Bioimaging Inc. is pleased to announce it has relocated its headquarters to 2 Park Plaza in downtown Boston. “This move helps facilitate Elucid’s ongoing expansion and provides increased proximity to research institutes, provider partners, and technology talent,” said CEO Blake Richards. Elucid is also pleased to announce the redesign and launch of its website (www.ElucidBio.com) to correspond with the move. “The website reflects and communicates our innovative product line that is pushing the boundaries in bringing new insights into the nexus of artificial intelligence and biological understanding to diagnose and treat cardiovascular disease,” stated Founder & CTO Andy Buckler.

Elucid Bioimaging is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its groundbreaking product, vascuCAP®, is the first FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, & plaque composition to inform risk of event (heart attack or stroke) and personalized treatment selection. vascuCAP® is in use by cardiologists, vascular surgeons, radiologists, and neurologists across the US and EU at health systems, clinics, and research institutes. vascuCAP® has applications for coronary, carotid, and peripheral arteries, and it is offered as an on-site deployed software or remotely conducted analysis.

Elucid is continuing to innovate with the development of non-invasive FFRct as measured by the direct cause rather than only simulations of its effect, which vascuCAP® is uniquely able to do from its unprecedented specificity in determining dynamic behavior of vessel walls. This functionality is currently available in vascuCAP® Research Edition. Elucid’s approach is also breaking ground as a basis for multi-scale modeling of molecular mechanisms of atherosclerosis, supported by CTAs paired with transcriptomics as an independent truth basis, with compelling results. These and other developments have been presented at ESC Congress 2019 and at ESVB 2019.